Newborn screening: An overview with an update on recent advances

Current Problems in Pediatric and Adolescent Health Care

Volumn 32, Issue 5, 2002, Pages 144-172

  Goodwin, Gregory ^a   Msall, Michael E ^a   Vohr, Betty R ^a   Rubin, Lewis P ^a   Padbury, James ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; BIOTINIDASE; BRANCHED CHAIN AMINO ACID; CYSTATHIONINE BETA SYNTHASE; DEXAMETHASONE; DNA; FLUDROCORTISONE; FOLINIC ACID; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; GLUCOCORTICOID; HYDROCORTISONE; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; MINERALOCORTICOID; PENICILLIN G; PHENYLALANINE 4 MONOOXYGENASE; PREDNISONE; PYRIMETHAMINE; SODIUM CHLORIDE; SPIRAMYCIN; SULFADIAZINE; SULFONAMIDE; THYROXINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE;

ARTICLE; BIOTINIDASE DEFICIENCY; CHRONIC DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; CONGENITAL TOXOPLASMOSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; GALACTOSEMIA; HEARING LOSS; HOMOCYSTINURIA; HUMAN; MAJOR CLINICAL STUDY; MAPLE SYRUP URINE DISEASE; MEDICAL TECHNOLOGY; METABOLIC DISORDER; MUTATIONAL ANALYSIS; NEWBORN; NEWBORN SCREENING; OUTCOMES RESEARCH; PATIENT EDUCATION; PHENYLKETONURIA; RESOURCE MANAGEMENT; SEPTICEMIA; SICKLE CELL ANEMIA; SIDE EFFECT; STREPTOCOCCUS INFECTION; SYMPTOMATOLOGY; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME;

EID: 0036588828     PISSN: 15385442     EISSN: None     Source Type: Journal    
DOI: 10.1067/mog.2002.122835     Document Type: Article

References (93)

1. Guthrie R. The origin of newborn screening. Screening 1992;1:5-15.
2. Koch JH. Robert Guthrie: the PKU story. Hope Publishing House: Pasadena, 1997.
3. Levy HL, Albers S. Genetic screening of newborns. Annu Rev Genomics Hum Genet 2000;01:139-77.
4. Guthrie R. Blood screening for phenylketonuria. JAMA 1961; 178:863-5.
5. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-43.
6. Phenylketonuria: screening and management. NIH Consensus Development Conference Statement online, October 16-18, 2000;17(3):1-27.
7. Committee on genetics. Newborn screening fact sheets. Pediatrics 1996;98:473-501.
8. Bickel H, Gerrard J, Hickmans E. Influence of phenylalanine intake on phenylketonuria. Lancet 1953;II:812.
9. Koch R, Blaskovics M, Wenz E, Fishler Schaeffler G. Phenylalaninemia and phenylketonuria. In: Nyhan WL, ed. Heritable disorders of amino acid metabolism. Toronto (CA): John Wiley & Sons; 1974. p. 109-40.
10. Wappner R, Cho S, Kronmal RA, Schuett V, Seashore MR. Management of phenylketonuria for optimal outcome: a review of guidelines for phenylketonuria management and a report of surveys of parents, patients, and clinic directors. Pediatrics 1999;104:e68.
11. Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, et al. Outcome at age 4 years in offspring of women with maternal phenylketonuria. JAMA 2000;283:756-62.
12. Chace DH, Sherwin JE, Hillman SL, Lorey F, Cunningham GC. Use of phenylalanine-to-tyrosine ratio determined by tandem mass spectrometry to improve newborn screening for phenylketonuria of early discharge specimens collected in the first 24 hours. Clin Chem 1998;44:2405-9.
13. Cornblath M, Schwartz R. Disorders of carbohydrate metabolism in infancy, 3rd ed. Cambridge (MA): Blackwell Scientific Publications, 1991.
14. Donnell GN. Disorders of galactose metabolism. In: Rudolf AM, Hoffman JIE, Rudolf CD, eds. Rudolf's pediatrics, 20th ed. Stamford (CT): Appleton & Lange; 1996. p. 326-8.
15. Waggoner DD, Buist NRM, Donnell GN. Long-term prognosis in galactosemia: results of a survey of 350 cases. J Inher Metab Dis 1990;13:802-18.
16. Holton JB, Walter JH, Tyfield LA. Galactosemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease. New York: McGraw-Hill; 2001. p. 1553-85.
17. Acosta PB, Yannicelli S. Nutrition support protocols. The Ross metabolic formula system. 4th ed. Columbus (OH): Ross Products Division; 2001.
18. Nyhan WL. Disorder of amino acid metabolism. In: Rudolph AM, Hoffman JIE, Rudolf CD, eds. Rudolf's pediatrics, 20th ed. Stamford (CT): Appleton & Lange; 1996. p. 307-22.
19. Mudd SH, Skovby F, Levy H, et al. The natural history of homocytinuria due to cystathionine-beta-synthase deficiency. Am J Hum Genet 1985;37:1-31.
20. Lees CM, Davies S, Dezateux C. Neonatal screening for sickle cell disease (Cochrane Review) In: The Cochrane Library, Issue 4. Oxford: Update Software; 2001.
21. Ashley-Koch A, Yang Q, Olney RS. Sickle hemoglobin (HbS allele and sickle cell disease: a HuGE review. Am J Epidemiol 2000;151:839-45.
22. Overturf GD, Powars D, Barraf LJ. Bacterial meningitis and septicemia in sickle cell disease. Am J Dis Child 1977;131: 784-7.
23. Rodgers D, Clarke J, Cupidore L, Ramlal AM, Sparke BR, Serjeant GR. Early deaths in Jamaican children with sickle cell disease. BMJ 1978;1:1515-6.
24. Gaston MH, Verter JL, Woods G, Pegelow C, Kelleher J, Presbury G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia: a randomized trial. N Engl J Med 1986;314:1593-9.
25. National Institutes of Health. Newborn screening for SCD and other hemoglobinopathics. JAMA 1987;258:1205-9.
26. Vichinsky E, Hurst D, Earles A, Kleman K, Lubin B. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 1988;81:749-54.
27. Githens JH, Lane PA, McCurdy RS, Houston ML, McKinna JD, Cole DM. Newborn screening for hemoglobinopathies in Colorado: the first 10 years. Am J Dis Child 1990;144:466-70.
28. Cunningham G, Lorey F, Kling S, Soper K, Urso F, Harris K, et al. Mortality among children with sickle cell disease identified by newborn screening during 1990-1994 in California, Illinois, and New York. MMWR 1998;47:169-72.
29. Davies SC, Cronin E, Gill M, Greengross P, Hickman M, Normand C. Screening for sickle cell disease and thalassaemia: a systemic review with supplementary research. Health Technol Assess 2000;4:1-99.
30. Karnon J, Zeuner D, Ades AE, Efimba W, Brown J, Yardumian A. The effects of neonatal screening for sickle cell disorders on lifetime treatment costs and early deaths avoided: a modelling approach. J Public Health Med 2000;22:500-11.
31. Joiner CH. Universal newborn screening for hemoglobinopathies. J Pediatr 2000;136:145-6.
32. Zarkowsky HS, Gallagher D, Gill FM, Wang WC, Falleta JM, Lande WM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986;109:579-85.
33. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease: Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-8.
34. + -thalassemia: is prophylactic penicillin necessary? J Pediatr 1995;127:348-54.
35. Wang WC, Wong W-Y, Rogers ZR, Wilimas JA, Buchanan GR, Powars DR. Antibiotic-resistant pneumococcal infection in children with sickle cell disease in the United States. J Pediatr Hematol Oncol 1996;18:140-4.
36. Pass K, Lane P, Fernhoff P, Hinton CF, Panny SR, Parks JS, et al. US Newborn Screening System Guidelines II: follow-up of children, diagnosis, management and evaluation-statement of Council of Regional Networks of Genetic Services (CORN). J Pediatr 2000;137:S1-46.
37. Sprinkle RH, Hynes DM, Konrad TR. Is universal neonatal hemoglobinopathy screening cost-effective? Arch Pediatr Adolesc Med 1994;148:461-9.
38. Panepinto JA, Magid D, Rewers MJ, Lane PA. Universal versus targeted screening of infants for sickle cell disease: a cost-effectiveness analysis. J Pediatr 2000;136:201-8.
39. Hurst D, Tittle B, Kleman KM, Embury SH, Lubin SH. Anemia and hemoglobinopathies in Southeast Asian refugee children. J Pediatr 1983;102:692-7.
40. Reed W, Lane PA, Bojanowski J, Glass M, Lubin BH, Vichinsky EP. Sickle-cell disease not identified by newborn screening because of prior transfusion. J Pediatr 2000;136: 248-50.
41. Bednarek FJ, Weisberger S, Richardson DK, Frantz ID 3rd, Shah B, Rubin LP. Variations in blood transfusions among newborn intensive care units. SNAP II Study Group. J Pediatr 1998;133:601-7.
42. Vaughan JL, Manning M, Warwick RM, Letsky EA, Murray NA, Roberts IA. Inhibition of erythroid progenitor cells by anti-Kell antibodies in fetal alloimmume anemia. N Engl J Med 1998;338:798-803.
43. Guerina NG, Hsu HW, Meissner HC, Maguire JH, Lynfield R, Stechenberg B, et al. Neonatal serologic screening and early treatment for congenital toxoplasma gondii infection: the New England Regional Toxoplasma Working Group. N Engl J Med 1994;330:1858-63.
44. Therrell BL, Berenbaum SA, Manter-Kapanke V, Simmank J, Korman K, Prentice L, et al. Results of screening 1.9 million newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998;101:583-90.
45. Pang S, Wallace MA, Hofman L, Thuline HC, Dorche C, Lyon ICT, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988;81:866-74.
46. New MI. Diagnosis and management of congenital adrenal hyperplasia. Annu Rev Med 1998;49:311-28.
47. Pang S, Hotchkiss J, Drash AL, Levine LS, New MI. Microfilter paper method for 17-hydroxyprogesterone radioimmunoassay: Its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1977;45:1003-8.
48. Allen DB, Hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997;130:128-33.
49. Dussault JH. The anecdotal history of screening for congenital hypothyroidism. J Clin Endocr Metab 1999;84:4332-4.
50. LaFranchi S. Recent developments in pediatric thyroidology. Thyroid Today 1998;21:1-13.
51. Gruters A. Congenital hypothyroidism. Pediatric Ann 1992; 21:15.
52. Newborn screening for congenital hypothyroidism: recommended guidelines - American Academy of Pediatrics Section on Endocrinology and committee on Genetics and American Thyroid Association Committee on Public Health. Pediatrics 1993;91:1203-9.
53. New England Congenital Hypothyroidism Collaborative. Characteristics of infantile hypothyroidism discovered on neonatal screening. J Pediatrics 1984;104:539-44.
54. Dubuis J, Glorieux J, Richer F, Deal CL, Dussault JH, Van Vliet G. Outcome of severe congenital hypothyroidism: closing the developmental gap with early high dose levothyroxine treatment. J Clin Endocr Metab 1996;81:222-7.
55. Bongers-Schokking JJ, Koot HM, Wiersma D, Verkerk PH, Keizer-Schrama S. Influence of timing and dose of thyroid hormone replacement on development in infants with congenital hypothyroidism. J Pediatrics 2000;136:292-7.
56. Fisher D. Euthyroid low thyroxine (T4) and triiodothyronine (T3) states in prematures and sick neonates. Pediatr Clin North Am 1990;37:1297-312.
57. Fort P, Lifshitz F, Bellisario R, Davis J, Lanes R, Pugliese M, et al. Abnormalities of thyroid function in infants with Down syndrome. J Pediatr 1984;104:545-9.
58. Welsh MJ, Ramsey BW, Accurso F, Cutting GR. Cystic fibrosis. In Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001. p. 5121-45.
59. Wang SS, Fitzsimmons SC, O'Leary LA, Rock MJ, Gwinn ML, Khoury MJ. Early diagnosis of cystic fibrosis in the newborn period and risk of pseudomonas aeruginosa acquisition in the first 10 years of life: a registry-based longitudinal study. Pediatr 2001;107:274-9.
60. Crossley JR, Elliot RB, Smith PA. Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1979;2:472-4.
61. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: A comparison of two strategies for case detection in 1.2 million babies. J Pediatrics 1995;127:965-70.
62. Newborn screening for cystic fibrosis: a paradigm for public health genetics policy development. Proceedings of a 1997 workshop. MMWR 1997;46(RR-16):1-23.
63. Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001;107:1-13.
64. Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis 1990;13:321-4.
65. Levy HL. Newborn screening by tandem mass spectrometry: a new era. Clinical Chemistry 1998;44:2401-2.
66. Using tandem mass spectrometry for metabolic disease screening among newborns. A report of a work group. MMWR 2001;50 (RR-3).
67. American College of Medical Genetics/American Society of Human Genetics Test and Technology Transfer committee Working Group. Tandem mass spectrometry in newborn screening. Genet Med 2000;2:267-9.
68. Neogen Screening Services. Available at: URL: www.neogenscreening.com. Accessed March 26, 2002.
69. Stanley CA. Inborn errors of lipid metabolism (mitochondrial fatty acid oxidation). In: Cowett RM, ed. Principles of perinatal-neonatal metabolism, 2nd ed. New York: Springer; 1998. p. 847-56.
70. Roe CR, Ding J. Mitochondrial fatty acid oxidation disorders. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular bases of inherited disease, 8th ed. New York: McGraw-Hill; 2001. p. 2297-326.
71. Boles RG, Buck EA, Blitzer MG, Platt MS, Cowan TM, Martin SK, et al. Retrospective biochemical screening of fatty acid oxidation disorders in postmortem livers of 418 cases of sudden death in the first year of life. J Pediatr 1998;132:924-33.
72. Ziadeh R, Hoffman EP, Finegold DN, Hoop RC, Brackett JC, Strauss AW, et al. Medium chain acyl-CoA dehydrogenase deficiency in Pennsylvania: neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995;37:675-8.
73. Marshall E. Fast technology drives new world of newborn screening. Science 2001;294:2272-4.
74. Iafolla AK, Thompson RJ, Roe CR. Medium-chain acyl-coenzyme A dehydrogenase deficiency: clinical course in 120 affected children. J Pediatr 1994;124:409-15.
75. Pollitt RJ, Leonard JV. Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child 1998;79:116-9.
76. Wilson CJ, Champion MP, Collins JE, Clayton PT, Leonard JV. Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child 1999;80:459-62.
77. Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, Frazier DM, et al. Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68:1408-18.
78. Cox GF, Souri M, Aoyama T, Rockenmacher S, Varvogli L, Rohr F, et al. Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acyl-coenzyme A dehydrogenase deficiency. J Pediatr 1998; 133:247-53.
79. Goodman SI, Frerman FE. Organic acidemias due to defects in lysine oxidation: 2-ketoadipic acidemia and glutaric acidemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic & molecular basis of inherited disease. 8th ed. 2001. p. 2195-204.
80. Vohr BR, Carty LM, Moore PE, Letourneau K. The Rhode Island hearing assessment program: experience with statewide hearing screening (1993-1996). J Pediatr 1998;133:353-7.
81. Task force on newborn screening and infant hearing. Newborn and infant hearing loss: detection and intervention. Pediatrics 1999;103:527-30.
82. Yoshinaga-Itano C, Sedey AL, Coulter DK, Mehl AL. Language of early- and later-identified children with hearing loss. Pediatrics 1998;102:1161-71.
83. Milusnsky Maher TA, Yosunkaya E, Vohr BR. Connexin-26 gene analysis in hearing-impaired newborns. Genetic Testing 2000;4:345-9.
84. Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 2000;154:714-8.
85. Serving the family from birth to the medical home: a report from the newborn screening task force. Pediatrics 2000; 106(suppl):383-423.
86. Stoddard JJ, Farrell PM. State-to-state variations in newborn screening policies. Arch Pediatr Adolesc Med 1997;151: 561-4.
87. Msall ME, Bier JB, LaGasse L, Tremont M, Lester B. The vulnerable preschool child: The impact of biomedical and social risks on neurodevelopmental function. Semin Pediatr Neurol 1998;5:52-61.
88. Msall ME, Tremont MR. Measuring functional status in children with genetic impairments. Am J Med Genet 1999;89:62-74.
89. Msall ME, Tremont MR, Ottenbacher KJ. Functional assessment of preschool children: optimizing developmental and family supports in early intervention. Infants and Young Children 2001;14:46-66.
90. Hogan DP, Msall ME. Family structure and resources and the parenting of children with disabilities and functional limitations. In: Borkowski JG, Landesman Ramey S, Bristol-Power M, eds. Parenting and child's world. London: Lawrence Erlbaum Associates; 2002 p. 311-27.
91. Curran AL, Sharples PM, White C, Knapp M. Time costs of caring for children with severe disabilities compared with caring for children without disabilities. Dev Med Child Neurol 2001;43:529-33.
92. Ireys HT, Wehr E, Cooke RE. Defining medical necessity: Strategies for promoting access to quality care for persons with developmental disabilities, mental retardation, and other special health care needs. Exceptional Parent 2000;30: 37-9.
93. American Academy of Pediatrics. The medical home [addendum AAP News, Nov 93]. Pediatrics 1992;90:774.